A Clinical Trial to test how well two drugs, QAW039 and Montelukast work both individually and together, to target allergic rhinitis using an environmental exposure chamber.

Registry ID

EUCTR2012-001389-14

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Novartis Pharma Services AG

Start date

2012-10-19

Completion date

2013-10-02

Last update

2026-08-16

Conditions

• allergic rhinitis

Summary

To evaluate the efficacy of QAW039 225 mg b.i.d and Montelukast 10 mg q.d administered together as a free combination compared to QAW039 225 mg b.i.d monotherapy in patients with grass pollen-induced intermittent allergic rhinitis in an EEC challenge model. This will be assessed by the Total Nasal Symptom Score (TNSS) averaged over the last two hours (2-4h) of exposure following 14 days treatment with QAW039 and/or Montelukast or matched placebo.

Locations

• , , Germany

View on source registry